Pulling SEC filings + quote and writing the call…

Disc Medicine, Inc.
Next earnings Aug 5, 2026 · consensus $-1.81 EPS
Last earnings -0.1% on 2026-05-05
Conservative balance sheet (liabilities/equity 0.09x).
Disc Medicine, Inc. shows limited reported revenue, and -28.7% ROE.
Sources: SEC EDGAR (CIK 0001816736, latest 10-Q filed 2026-05-05) · EODHD · as of 6/25/2026, 4:05:18 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$30.9M | -$47.5M | -$91.1M | -$130M | -$236M |
| Net income | -$36.0M | -$46.8M | -$76.4M | -$109M | -$212M |
| Diluted EPS | -$40.95 | -$45.05 | -$3.42 | -$3.96 | -$6.01 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1072 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 7 sales
| 2026-06-22 | Yu Jonathan Yen-Wen Chief Operating Officer | Exercise | 9.70K @ $13.50 | $131K |
| 2026-06-22 | Yu Jonathan Yen-Wen Chief Operating Officer | Sell | 9.70K @ $72.66 | $705K |
| 2026-06-18 | Khara Rahul Chief Legal Officer | Exercise | 7.50K @ $14.69 | $110K |
| 2026-06-18 | Khara Rahul Chief Legal Officer | Sell | 5.40K @ $69.94 | $378K |
| 2026-06-18 | Khara Rahul Chief Legal Officer | Sell | 1.60K @ $70.73 | $113K |
| 2026-06-18 | Khara Rahul Chief Legal Officer | Sell | 500.00 @ $71.62 | $35.8K |
| 2026-06-18 | Quisel John D Chief Executive Officer | Exercise | 34.0K @ $9.86 | $335K |
| 2026-06-18 | Quisel John D Chief Executive Officer | Sell | 22.9K @ $69.92 | $1.60M |
| 2026-06-18 | Quisel John D Chief Executive Officer | Sell | 9.52K @ $70.70 | $673K |
| 2026-06-18 | Quisel John D Chief Executive Officer | Sell | 1.55K @ $71.61 | $111K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.